Page 138 - 202005

[24] WU T，QIAO Q，QIN X，et al. Immunostimulatory cyto- （3）：2387-2392.
kine and doxorubicin co-loaded nanovesicles for cancer [39] HANDY CE，ANTONARAKIS ES. Sipuleucel-T for the
immunochemotherapy[J]. Nanomedicine，2019.DOI：10. treatment of prostate cancer：novel insights and future di-
1016/j.nano.2019.02.008. rections[J]. Future Oncol，2018，14（10）：907-917.
[25] 陈曦，祝星宇，马博乐，等.基于肿瘤微环境的纳米靶向载 [40] APOSTOLOPOULOS V. Cancer vaccines：research and
体研究进展[J].中国药房，2017，28（13）：1864-1868. applications[J]. Cancers：Basel，2019.DOI：10.3390/can-
[26] SONG Q，YIN Y，SHANG L，et al. Tumor microenviron- cers11081041.
ment responsive nanogel for the combinatorial antitumor [41] FANG RH，HU CM，LUK BT，et al. Cancer cell mem-
effect of chemotherapy and immunotherapy[J]. Nano Lett， brane-coatednanoparticles for anticancer vaccination and
2017，17（10）：6366-6375. drug delivery[J]. Nano Lett，2014，14（4）：2181-2188.
[27] SLIWKOWSKI MX，MELLMAN I. Antibody therapeu- [42] LIU WL，ZOU MZ，LIU T，et al. Cytomembrane nanovac-
tics in cancer[J]. Science，2013 ，341（6151）：1192-1198. cines showtherapeutic effects by mimicking tumor cells
[28] BUCHBINDER E，HODI FS. Cytotoxic T lymphocyte an- and antigen presenting cells[J]. Nat Commun，2019.DOI：
tigen-4 and immune checkpoint blockade[J]. J Clin Invest， 10.1038/s41467-019-11157-1.
2015，125（9）：3377-3383. [43] GUO Y，WANG D，SONG Q，et al. Erythrocyte mem-
[29] FRITZ JM，LENARDO MJ. Development of immune brane-enveloped polymeric nanoparticles as nanovaccine
checkpoint therapy for cancer[J]. J Exp Med，2019，216 for induction of antitumor immunity against melanoma[J].
（6）：1244-1254. ACS Nano，2015，9（7）：6918-6933.
[30] INTHAGARD J，EDWARDS J，ROSEWEIR AK. Immu- [44] CHU D，DONG X，SHI X，et al. Neutrophil-based drug de-
notherapy：enhancing the efficacy of this promising thera- livery systems[J]. Adv Mater，2018.DOI：10.1002/adma.
peutic in multiple cancers[J]. Clin Sci：Lond，2019，133 201706245.
（2）：181-193. [45] OLSON DJ，LUKE JJ. The T-cell-inflamed tumor micro-
[31] ALTMANN DM. A nobel prize-worthy pursuit：cancer im- environment as a paradigm for immunotherapy drug devel-
munology and harnessing immunity to tumour neoantigens opment[J]. Immunotherapy，2019，11（3）：155-159.
[J]. Immunology，2018，155（3）：283-284. [46] SZCZERBA BM，CASTRO-GINER F，VETTER M，et al.
[32] GAO L，HAN L，DING X，et al. An effective intracellular Neutrophils escort circulating tumour cells to enable cell
delivery system of monoclonal antibody for treatment of cycle progression[J]. Nature，2019，566（7745）：553-557.
tumors：erythrocyte membrane-coated self-associated anti- [47] KANG T，ZHU Q，WEI D，et al. Nanoparticles coated
body nanoparticles[J]. Nanotechnology，2017.DOI：10. with neutrophil membranes can effectively treat cancer
1088/1361-6528/aa7c43. metastasis[J]. ACS Nano，2017，11（2）：1397-1411.
[33] 田浩，陈世春，韩雨彤，等.生物膜仿生纳米颗粒在药物传 [48] QUARANTA V，SCHMID MC. Macrophage-mediated
递体系中的研究进展[J].中国医药导报，2018，15（7）： subversion of anti-tumour immunity[J]. Cell，2019.DOI：
31-35. 10.3390/cells8070747.
[34] LIU X，LIU C，ZHENG Z，et al. Vesicular antibodies：a [49] CHOO YW，KANG M，KIM HY，et al. M1 macrophage-
bioactive multifunctional combination platform for target- derived nanovesicles potentiate the anticancer efficacy of
ed therapeutic delivery and cancer immunotherapy[J]. Adv immune checkpoint inhibitors[J]. ACS Nano，2018，12（9）：
Mater，2019.DOI：10.1002/adma.201808294. 8977-8993.
[35] FONTANA F，FUSCIELLO M，GROENEVELDT C， [50] JOYCE JA，REARON DT. T cell exclusion，immune privi-
et al. Biohybrid vaccines for improved treatment of ag- lege，and the tumor microenvironment[J]. Science，2015，
gressive melanoma with checkpoint inhibitor[J]. ACS Na- 348（6230）：74-80.
no，2019，13（6）：6477-6490. [51] GAMMON JM，DOLD NM，JEWELL CM. Jewell，im-
[36] ZHANG X，WANG C，WANG J，et al. PD-1 blockade cel- proving the clinical impact of biomaterials in cancer im-
lular vesicles for cancer immunotherapy[J]. Adv Mater， munotherapy[J]. Oncotarget，2016，7（13）：15421-15443.
2018.DOI：10.1002/adma.201707112. [52] LIU J，ZHANG R，XU ZP. Nanoparticle-based nanomedi-
[37] WANG C，SUN W，YE Y，et al. In situ activation of plate- cines to promote cancer immunotherapy：recent advances
lets with checkpoint inhibitors for post-surgical cancer im- and future directions[J]. Small，2019.DOI：10.1002/smll.
munotherapy[J]. Nature Biomedical Engineering，2017，1 201900262.
（2）：1-10. （收稿日期：2019-10-17 修回日期：2020-01-10）
[38] ZHU G，ZHANG F，NI Q，et al. Efficient nanovaccine de- （编辑：唐晓莲）
livery in cancer immunotherapy[J]. ACS Nano，2017，11

·640 · China Pharmacy 2020 Vol. 31 No. 5 中国药房 2020年第31卷第5期